NasdaqGS:EWTXPharmaceuticals
Why Edgewise Therapeutics (EWTX) Is Up 13.3% After Phase 2 EDG-7500 HCM Data Release
Edgewise Therapeutics recently reported positive top-line 12-week Phase 2 Part D CIRRUS-HCM results for EDG-7500 in both obstructive and nonobstructive hypertrophic cardiomyopathy, showing clinically meaningful improvements in hemodynamics, heart failure biomarkers, patient-reported outcomes and functional status, with generally well-tolerated safety.
A distinctive aspect of these data is the apparent preservation of systolic function across more than 700 echocardiograms while still...

